From San Francisco Business Times, BiotechSF
Like the journey of a thousand miles, the path leading to an Alzheimer's disease treatment begins with a single step: Getting people through the doors of hundreds of clinical trial sites.
Now a program based at the University of California, San Francisco, is teaming up with a global foundation to build out a registry of current and potential Alzheimer's patients from which the right people can be quickly assigned to the right drug studies.
The Brain Health Registry is a matter of time and money, said Dr. Michael Weiner, director of the registry and a professor of radiology and biomedical engineering, medicine, psychiatry and neurology at UCSF. It could potentially accelerate clinical trials by cutting down on the time it takes to enroll study participants.